Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma ” or the “Company ”), a biopharmaceutical ...

Highlights advancement of first-in-class neuroprotective candidate targeting demyelinationTORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ...

In the coming weeks, Quantum Biopharma will seek FDA permission for a clinical trial testing Lucid-MS, its therapy to slow myelin loss in MS.

Funded by the National Multiple Sclerosis Society, the study aims to identify care gaps and develop resources for women with ...

Project MS Shift aims to raise awareness and access to Delawareans — especially Black Delawareans — who are impacted by ...

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

While each method has its pros and cons, a joint study found that LC-MS provides a clearer, more comprehensive picture of the ...

The RPLC-MS analysis successfully identified 90 circulating metabolites—including 14 of microbial origin—and demonstrated ...

By driving a robust culture of innovation, the hub will provide a collaborative space to test and scale solutions with ...

‘We have six months to save our daughter’s life before childhood dementia robs her of her future’ - Family of two-year-old ...

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful ...

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative ...